Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research1,190

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research1,190

FiltersClear all

Status

Recruiting350
Not yet recruiting11
Enrolling by invitation17
Active, not recruiting322
Completed358
Terminated132

Study type

Interventional1,190
Observational101
Expanded access19
Not on ClinicalTrials.gov1,519

Phase

Phase 3325
Not applicable304
Phase 2286
Phase 1103
Phase 1/277
Phase 454

Investigator

Gail J Roboz41
Manish A Shah27
Parag Goyal23
Sonal Kumar23
Scott T. Tagawa22

Show all 50Show fewer

Department

Medicine750
Pediatrics81
Neurology46
Psychiatry46
Obstetrics and Gynecology41

Show all 22Show fewer

Condition

Leukemia, Myeloid, Acute50
Prostatic Neoplasms49
Breast Neoplasms41
Heart Failure31
Neoplasms31

Show all 50

Intervention type

Drug788
Other176
Device166
Biological150
Procedure119
Behavioral83

Sponsor type

Industry685
WCM (investigator-initiated)230
Other academic173
NIH76
Cooperative group25
Unknown1

Start date

Has results posted342

Interventional×Clear all

Showing 161–180 of 1,190 studiesSort:

RecruitingInterventional · Not applicableNCT04339699 ↗
STITCH - Prospective Multi Center Comparative Parallel Concurrent Study of the NobleStitch EL Compared to FDA Approved Amplatzer Occluder Device for Closure of Patent Foramen Ovale to Prevent Recurrent Ischemic Stroke
Harsimran SinghPI
Intervention
Device: NobleStitch™EL Suture Mediated Closure System · Device: Amplatzer PFO Occluder

FiltersClear all

Status

Recruiting350
Not yet recruiting11
Enrolling by invitation17
Active, not recruiting322
Completed358
Terminated132

Study type

Interventional1,190
Observational101
Expanded access19
Not on ClinicalTrials.gov1,519

Phase

Phase 3325
Not applicable304
Phase 2286
Phase 1103
Phase 1/277
Phase 454

Investigator

Gail J Roboz41
Manish A Shah27
Parag Goyal23
Sonal Kumar23
Scott T. Tagawa22

Show all 50Show fewer

Department

Medicine750
Pediatrics81
Neurology46
Psychiatry46
Obstetrics and Gynecology41

Show all 22Show fewer

Condition

Leukemia, Myeloid, Acute50
Prostatic Neoplasms49
Breast Neoplasms41
Heart Failure31
Neoplasms31

Show all 50

Intervention type

Drug788
Other176
Device166
Biological150
Procedure119
Behavioral83

Sponsor type

Industry685
WCM (investigator-initiated)230
Other academic173
NIH76
Cooperative group25
Unknown1

Start date

Has results posted342

Interventional×Clear all

Showing 161–180 of 1,190 studiesSort:

RecruitingInterventional · Not applicableNCT04339699 ↗
STITCH - Prospective Multi Center Comparative Parallel Concurrent Study of the NobleStitch EL Compared to FDA Approved Amplatzer Occluder Device for Closure of Patent Foramen Ovale to Prevent Recurrent Ischemic Stroke
Harsimran SinghPI
Intervention
Device: NobleStitch™EL Suture Mediated Closure System · Device: Amplatzer PFO Occluder

Phase 2/3

Early phase 13

Harini Sarva21
Ashish Saxena20
Cora Sternberg20
Ellen K. Ritchie18
Ruben Niesvizky16
Dana Jeremy Lukin14
Evelyn M. Horn14
Pinkal Desai14
Ellen J Scherl13
Daniel W Skupski12
Eleni Andreopoulou12
Jim W. Cheung12
Jia Ruan12
Massimo Cristofanilli12
Sujit Sheth12
Catherine Butkus Small11
James E. Ip11
John Allan11
Anna C Pavlick10
Alexander Ja-Ho Chou10
Aliza B Solomon10
Alpana P. Shukla10
Marshall J. Glesby10
Anna Podolanczuk9
Barbara Ma9
Catherine McGuinn9
Silvia Chiara Formenti9
Hani Lamie Ashamalla9
Kristen Marks9
Robert J. Kaner9
Shari Lipner9
Maria Teresa DeSancho8
Samuel Kim8
Andrew F. Alexis7
Erin Mulvey7
Evelyn Cantillo7
Jean W. Pape7
Sebastian A. Mayer7
Brian DeRubertis6
Conor Liston6
Darshana M Dadhania6
David M Nanus6
Joseph M Scandura6
Lok W. Yung6
Mehraneh Dorna Jafari6

Neurological Surgery19

Cardiothoracic Surgery17

Urology15

Rehabilitation Medicine13

Population Health Sciences9

Otolaryngology Head and Neck Surgery7

Pathology and Laboratory Medicine1

Pharmacology1

Show fewer

Carcinoma, Non-Small-Cell Lung27
Multiple Myeloma27
Colitis, Ulcerative26
Crohn Disease26
Myelodysplastic Syndromes26
Recurrence25
Atrial Fibrillation23
Neoplasm Metastasis23
Obesity23
Parkinson Disease21
COVID-1920
Colorectal Neoplasms18
Depression18
Cardiovascular Diseases17
Hematologic Neoplasms17
HIV Infections16
Non-alcoholic Fatty Liver Disease15
Overweight15
Melanoma13
Idiopathic Pulmonary Fibrosis12
Inflammatory Bowel Diseases12
Leukemia, Lymphocytic, Chronic, B-Cell12
Lung Neoplasms12
Lymphoma, Non-Hodgkin12
Primary Myelofibrosis12
Hypertension11
Myeloproliferative Disorders11
Alzheimer Disease10
Coronary Artery Disease10
Hypertension, Pulmonary10
Leukemia, Myelomonocytic, Chronic10
Stroke10
Urinary Bladder Neoplasms10
Cognitive Dysfunction9
Leukemia9
Lung Diseases, Interstitial9
Pulmonary Arterial Hypertension9
Burkitt Lymphoma8
Carcinoma, Renal Cell8
Chronic Pain8
Fibrosis8
Lymphoma, Follicular8
Lymphoma, Large B-Cell, Diffuse8
Adenocarcinoma Of Esophagus7
Anemia7

Radiation

Diagnostic test22

Dietary supplement14

Combination product11

Genetic6

Dates

Jan 2021 – Dec 2026 (est.)

Sponsor

Nobles Medical Technologies II, Inc.

Foramen Ovale, PatentStroke, Ischemic

Active, not recruitingInterventional · Phase 1NCT04340596 ↗

A Phase I Clinical Trial of the Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

Marshall J. GlesbyPI

Intervention: Biological: N-803 (IL-15 Superagonist) · Biological: VRC07-523LS · Biological: 10-1074
Dates: May 2021 – May 2026
Sponsor: National Institute of Allergy & Infectious Diseases

HIV Infection

RecruitingInterventional · Not applicableNCT04371913 ↗

Personalized Second Chance Breast Conservation (PSCBC): A Two Center Prospective Phase II Clinical Study

John NgPI

Intervention: Radiation: 600cGY x 5 fractions APBI · Radiation: 270cGy x 15 fractions WBRT
Dates: Jun 2020 – Dec 2030 (est.)
Sponsor: Weill Medical College of Cornell University

Breast Cancer

Active, not recruitingInterventional · Not applicableNCT04375332 ↗

A Prospective, Multi-center Trial to Evaluate the Safety and Effectiveness of Beating Heart Mitral Valve Repair With the HARPOON™ System (RESTORE)

Stephanie L. MickPI

Intervention: Device: HARPOON™ Beating Heart Mitral Valve Repair System
Dates: Dec 2020 – Dec 2027 (est.)
Sponsor: Edwards Lifesciences Corp.

Mitral Regurgitation

Active, not recruitingInterventional · Phase 2NCT04395222 ↗

A Prospective Study of Tocilizumab for the Prevention of Graft Failure and Graft-versus-Host Disease in Haplo-Cord Transplantation

Alexandra Gomez ArteagaPI

Intervention: Drug: Tocilizumab · Drug: Fludarabine · Drug: Melphalan · Drug: Anti-thymocyte globulin (rabbit) · Radiation: Total Body Irradiation
Dates: Oct 2020 – Sep 2022· Results posted
Sponsor: Weill Medical College of Cornell University

Hematologic MalignancyBone Marrow Transplant

Active, not recruitingInterventional · Phase 3NCT04401748 ↗

A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Azacitidine in Patients Newly Diagnosed With Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS)

Gail J RobozPI

Intervention: Drug: Venetoclax · Drug: Azacitidine · Drug: Placebo
Dates: Sep 2020 – Jul 2027 (est.)
Sponsor: AbbVie Inc.

Myelodysplastic Syndrome (MDS)

RecruitingInterventional · Phase 2NCT04402151 ↗

Single-Arm Phase II Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer

Silvia Chiara FormentiPI

Intervention: Drug: PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC · Radiation: Stereotactic Body Radiation Therapy (SBRT)
Dates: Jun 2020 – Dec 2027 (est.)
Sponsor: Weill Medical College of Cornell University

Prostate Cancer

Active, not recruitingInterventional · Phase 1NCT04420754 ↗

A Multicenter Phase I Study of AIC100 CAR T Cells in Relapsed and/or Refractory Advanced Thyroid Cancer or Anaplastic Thyroid Cancer

Sebastian A. MayerPI

Intervention: Biological: AIC100 CAR T Cells
Dates: Sep 2020 – Aug 2026 (est.)
Sponsor: AffyImmune Therapeutics Inc.

Anaplastic Thyroid CancerRelapsed/Refractory Poorly Differentiated Thyroid Cancer

Active, not recruitingInterventional · Phase 2NCT04422132 ↗

Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks

Emily WegPI

Intervention: Radiation: 5 days Radiation Therapy (32.5 Gy in 5 fractions) · Radiation: 20 days Radiation therapy (55 Gy in 20 fractions)
Dates: Sep 2020 – Dec 2025· Results posted
Sponsor: Weill Medical College of Cornell University

Prostate Cancer

Enrolling by invitationInterventional · Phase 1/2NCT04432623 ↗

A Phase 1b Sequential Open Label Dose-Ranging Study of Safety, Pharmacokinetics, and Preliminary Activity of Benserazide in Subjects With Beta Thalassemia Intermedia and Sickle Cell Disease

Sujit ShethPI

Intervention: Drug: Benserazide Only Product
Dates: Oct 2020 – Feb 2026 (est.)
Sponsor: Phoenicia BioSciences, Inc.

Beta Thalassemia IntermediaSickle Cell Disease

Active, not recruitingInterventional · Phase 1NCT04454658 ↗

A Phase 1b Study Of ABBV-744 Alone Or In Combination With Ruxolitinib Or Navitoclax In Subjects With Myelofibrosis

Ellen K. RitchiePI

Intervention: Drug: ABBV-744 · Drug: Navitoclax · Drug: Ruxolitinib
Dates: Nov 2020 – Jan 2027 (est.)
Sponsor: AbbVie Inc.

Myelofibrosis (MF)

Active, not recruitingInterventional · Phase 3NCT04455750 ↗

CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer

Scott T. TagawaPI

Intervention: Drug: Enzalutamide · Drug: Rucaparib camsylate · Drug: Placebo · Drug: Leuprolide Acetate · Drug: Goserelin Acetate · Drug: Degarelix · Other: Quality-of-Life Assessment · Other: Questionnaire Administration
Dates: Oct 2021 – Mar 2027 (est.)
Sponsor: Alliance for Clinical Trials in Oncology

Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IV Prostate Cancer AJCC v8+2 more

RecruitingInterventional · Phase 3NCT04462770 ↗

A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Children and Adult Participants With Dravet Syndrome (ARGUS Trial)

Zachary GrinspanPI

Intervention: Drug: Clemizole HCl · Drug: Placebo
Dates: Sep 2020 – Apr 2027 (est.)
Sponsor: Epygenix Therapeutics, Inc

Dravet Syndrome

Active, not recruitingInterventional · Not applicableNCT04482062 ↗

Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy Using a Novel Device

Shmuel ChenPI

Intervention: Device: Edwards EVOQUE System · Drug: Optimal Medical Therapy
Dates: Apr 2021 – Dec 2025
Sponsor: Edwards Lifesciences Corp.

Tricuspid Valve RegurgitationTricuspid Valve InsufficiencyTricuspid Valve Disease+3 more

Active, not recruitingInterventional · Phase 2NCT04485949 ↗

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma

Rohan RamakrishnaPI

Intervention: Combination product: IGV-001 Cell Immunotherapy · Combination product: Placebo · Procedure: Standard of Care (SOC): Radiation Therapy · Drug: SOC: Temozolomide
Dates: Mar 2023 – Jan 2027 (est.)
Sponsor: Imvax, Inc.

Glioblastoma

RecruitingInterventional · Phase 1/2NCT04486352 ↗

A Phase IB/II Multi-Cohort Study of Targeted Agents and/or Immunotherapy With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer

Evelyn CantilloPI

Intervention: Drug: Atezolizumab - 28 Day Cycle · Drug: Bevacizumab · Drug: Ipatasertib · Drug: Talazoparib · Drug: Trastuzumab emtansine · Drug: Tiragolumab · Drug: Atezolizumab - 21 Day Cycle · Drug: Inavolisib · Drug: Letrozole · Drug: Giredestrant · Drug: Abemaciclib
Dates: Oct 2021 – Oct 2026 (est.)
Sponsor: Alliance Foundation Trials, LLC

Endometrial Cancer

Active, not recruitingInterventional · Phase 2NCT04486378 ↗

A Multi-site, Open-label, Phase II, Randomized, Controlled Trial to Compare the Efficacy of RO7198457 Versus Watchful Waiting in Resected, Stage II (High Risk) and Stage III Colorectal Cancer Patients Who Are ctDNA Positive Following Resection

Manish A ShahPI

Intervention: Drug: RO7198457 intravenous (IV) · Other: Observational group (no intervention)
Dates: Mar 2021 – Nov 2026 (est.)
Sponsor: BioNTech SE

Colorectal Cancer Stage IIColorectal Cancer Stage III

Active, not recruitingInterventional · Not applicableNCT04489823 ↗

PARADIGM PARAvalvular Leak Closure With the Amplatzer Valvular Plug occluDer for Interventional Transcatheter Closure for PVL With Surgical bioloGical and Mechanical Heart Valve

Geoffrey W BergmanPI

Intervention: Device: AVP III
Dates: Dec 2020 – Nov 2025
Sponsor: Abbott Cardiovascular Systems, Inc.

Paravalvular Aortic Regurgitation

Active, not recruitingInterventional · Phase 3NCT04490915 ↗

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment

Oksana LekarevPI

Intervention: Drug: Crinecerfont · Drug: Placebo
Dates: Dec 2020 – Jul 2023· Results posted
Sponsor: Neurocrine Biosciences INC

Congenital Adrenal Hyperplasia

Active, not recruitingInterventional · Phase 1NCT04506567 ↗

Phase I/II Dose-escalation Study of Fractionated and Multiple Dose 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

Joseph Reginald OsbornePI

Intervention: Drug: Multiple Dose of 225Ac-J591 at 45 KBq/kg · Drug: Multiple Dose of 225Ac-J591 at 55 KBq/kg · Drug: Multiple Dose of 225Ac-J591 at 65 KBq/kg · Drug: Fractionated Dose of 225Ac-J591 at 45 KBq/kg · Drug: Fractionated Dose of 225Ac-J591 at 55 KBq/kg · Drug: Fractionated Dose of 225Ac-J591 at 60 KBq/kg · Drug: Fractionated Dose of 225Ac-J591 at 65 KBq/kg · Drug: Fractionated Dose of 225Ac-J591 at 45 KBq/kg (Prior 177Lu-PSMA-RL) · Drug: Fractionated Dose of 225Ac-J591 at 50 KBq/kg (Prior 177Lu-PSMA-RL) · Diagnostic test: 68Ga-PSMA-HBED-CC injection
Dates: Aug 2020 – Jun 2025· Results posted
Sponsor: Weill Medical College of Cornell University

Prostate Cancer

‹ Prev 1 2 3 4 5…8 9 10…56 57 58 59 60 Next ›